

Louis Vermeulen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5299288/publications.pdf>

Version: 2024-02-01

118
papers

16,808
citations

47006

47
h-index

25787

108
g-index

126
all docs

126
docs citations

126
times ranked

22423
citing authors

#	ARTICLE	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	30.7	3,596
2	Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. <i>Nature Cell Biology</i> , 2010, 12, 468-476.	10.3	1,623
3	Colon Cancer Stem Cells Dictate Tumor Growth and Resist Cell Death by Production of Interleukin-4. <i>Cell Stem Cell</i> , 2007, 1, 389-402.	11.1	968
4	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 79-92.	28.4	686
5	Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. <i>Nature Medicine</i> , 2013, 19, 614-618.	30.7	656
6	Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13427-13432.	7.1	654
7	Intestinal label-retaining cells are secretory precursors expressing Lgr5. <i>Nature</i> , 2013, 495, 65-69.	27.8	653
8	From tumour heterogeneity to advances in precision treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 235-246.	27.6	466
9	Cancer Stem Cell Niche: The Place to Be. <i>Cancer Research</i> , 2011, 71, 634-639.	0.9	460
10	Microenvironmental regulation of stem cells in intestinal homeostasis and cancer. <i>Nature</i> , 2011, 474, 318-326.	27.8	399
11	Defining Stem Cell Dynamics in Models of Intestinal Tumor Initiation. <i>Science</i> , 2013, 342, 995-998.	12.6	355
12	The developing cancer stem-cell model: clinical challenges and opportunities. <i>Lancet Oncology</i> , The, 2012, 13, e83-e89.	10.7	327
13	The AC133 Epitope, but not the CD133 Protein, Is Lost upon Cancer Stem Cell Differentiation. <i>Cancer Research</i> , 2010, 70, 719-729.	0.9	326
14	Cancer stem cells – old concepts, new insights. <i>Cell Death and Differentiation</i> , 2008, 15, 947-958.	11.2	320
15	Methylation of Cancer-Stem-Cell-Associated Wnt Target Genes Predicts Poor Prognosis in Colorectal Cancer Patients. <i>Cell Stem Cell</i> , 2011, 9, 476-485.	11.1	291
16	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	2.8	239
17	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	8.1	227
18	Cancer heterogeneity – a multifaceted view. <i>EMBO Reports</i> , 2013, 14, 686-695.	4.5	208

#	ARTICLE	IF	CITATIONS
19	Stem cell dynamics in homeostasis and cancer of the intestine. <i>Nature Reviews Cancer</i> , 2014, 14, 468-480.	28.4	206
20	Targeting Wnt Signaling in Colon Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2011, 17, 647-653.	7.0	199
21	Continuous Clonal Labeling Reveals Small Numbers of Functional Stem Cells in Intestinal Crypts and Adenomas. <i>Cell Stem Cell</i> , 2013, 13, 626-633.	11.1	188
22	Cancer Stem Cell Tumor Model Reveals Invasive Morphology and Increased Phenotypical Heterogeneity. <i>Cancer Research</i> , 2010, 70, 46-56.	0.9	180
23	Wnt Signaling in Cancer Stem Cell Biology. <i>Cancers</i> , 2016, 8, 60.	3.7	180
24	Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. <i>Cancer Research</i> , 2015, 75, 245-249.	0.9	163
25	Serrated neoplasia's role in colorectal carcinogenesis and clinical implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 401-409.	17.8	149
26	Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer. <i>Nature Cell Biology</i> , 2018, 20, 1193-1202.	10.3	138
27	DeepCC: a novel deep learning-based framework for cancer molecular subtype classification. <i>Oncogenesis</i> , 2019, 8, 44.	4.9	138
28	Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models. <i>Cell Death and Differentiation</i> , 2018, 25, 616-633.	11.2	137
29	Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer. <i>Cancer Research</i> , 2008, 68, 1213-1220.	0.9	130
30	CFTR is a tumor suppressor gene in murine and human intestinal cancer. <i>Oncogene</i> , 2016, 35, 4191-4199.	5.9	129
31	Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. <i>Clinical Cancer Research</i> , 2017, 23, 387-398.	7.0	128
32	TGF β 2 signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. <i>EMBO Molecular Medicine</i> , 2016, 8, 745-760.	6.9	119
33	Apc-mutant cells act as supercompetitors in intestinal tumour initiation. <i>Nature</i> , 2021, 594, 436-441.	27.8	108
34	Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2229.	4.1	105
35	Molecular subtypes in cancers of the gastrointestinal tract. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 333-342.	17.8	99
36	The effect of environmental chemicals on the tumor microenvironment. <i>Carcinogenesis</i> , 2015, 36, S160-S183.	2.8	97

#	ARTICLE	IF	CITATIONS
37	Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. <i>Oncogene</i> , 2016, 35, 5263-5271.	5.9	87
38	ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy. <i>Cell Reports</i> , 2015, 13, 489-494.	6.4	83
39	Mutations in the Ras/Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3132-3141.	7.0	79
40	Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2022, 114, 503-516.	6.3	70
41	Reconciliation of classification systems defining molecular subtypes of colorectal cancer. <i>Cell Cycle</i> , 2014, 13, 353-357.	2.6	69
42	Spatiotemporal regulation of clonogenicity in colorectal cancer xenografts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6140-6145.	7.1	60
43	Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data. <i>British Journal of Cancer</i> , 2018, 119, 1244-1251.	6.4	57
44	A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities. <i>Nature Communications</i> , 2020, 11, 2935.	12.8	57
45	Bcl-2 is a critical mediator of intestinal transformation. <i>Nature Communications</i> , 2016, 7, 10916.	12.8	55
46	Itraconazole targets cell cycle heterogeneity in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 1891-1912.	8.5	54
47	Kinome Analysis Reveals Nongenomic Glucocorticoid Receptor-Dependent Inhibition of Insulin Signaling. <i>Endocrinology</i> , 2006, 147, 3555-3562.	2.8	53
48	Modeling Evolutionary Dynamics of Epigenetic Mutations in Hierarchically Organized Tumors. <i>PLoS Computational Biology</i> , 2011, 7, e1001132.	3.2	53
49	Regulation of stem cell self-renewal and differentiation by Wnt and Notch are conserved throughout the adenoma-carcinoma sequence in the colon. <i>Molecular Cancer</i> , 2013, 12, 126.	19.2	50
50	A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. <i>Oncogene</i> , 2016, 35, 6026-6037.	5.9	49
51	Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classification systems. <i>Scientific Reports</i> , 2020, 10, 337.	3.3	46
52	Stem cells in homeostasis and cancer of the gut. <i>Molecular Cancer</i> , 2019, 18, 66.	19.2	44
53	Chromosomal copy number heterogeneity predicts survival rates across cancers. <i>Nature Communications</i> , 2021, 12, 3188.	12.8	43
54	Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. <i>Oncogene</i> , 2019, 38, 2305-2319.	5.9	41

#	ARTICLE	IF	CITATIONS
55	Predictors of 30-Day Mortality Among Dutch Patients Undergoing Colorectal Cancer Surgery, 2011-2016. <i>JAMA Network Open</i> , 2021, 4, e217737.	5.9	37
56	Neoadjuvant chemotherapy affects molecular classification of colorectal tumors. <i>Oncogenesis</i> , 2017, 6, e357-e357.	4.9	35
57	Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence. <i>British Journal of Cancer</i> , 2016, 115, 1565-1574.	6.4	34
58	Exploring cancer stem cell niche directed tumor growth. <i>Cell Cycle</i> , 2010, 9, 1472-1479.	2.6	32
59	Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry. <i>Methods in Molecular Biology</i> , 2018, 1765, 179-191.	0.9	31
60	Emerging Role and Therapeutic Potential of lncRNAs in Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3843.	3.7	29
61	Dissecting cancer heterogeneity – An unsupervised classification approach. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 2574-2579.	2.8	28
62	Turning Cold Tumors Hot by Blocking TGF- β 2. <i>Trends in Cancer</i> , 2018, 4, 335-337.	7.4	26
63	Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. <i>Gastroenterology</i> , 2017, 153, 63-76.e14.	1.3	25
64	Primary tumour immune response and lymph node yields in colon cancer. <i>British Journal of Cancer</i> , 2022, 126, 1178-1185.	6.4	24
65	The interplay between intrinsic and extrinsic Wnt signaling in controlling intestinal transformation. <i>Differentiation</i> , 2019, 108, 17-23.	1.9	23
66	CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status. <i>PLoS ONE</i> , 2013, 8, e72849.	2.5	23
67	One renegade cancer stem cell?. <i>Cell Cycle</i> , 2009, 8, 803-808.	2.6	22
68	Bidirectional interconversion of stem and non-stem cancer cell populations: A reassessment of theoretical models for tumor heterogeneity. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1098791.	0.7	19
69	Fusion of intestinal epithelial cells with bone marrow derived cells is dispensable for tissue homeostasis. <i>Scientific Reports</i> , 2012, 2, 271.	3.3	17
70	Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 283-296.	3.0	17
71	A mouse model for peritoneal metastases of colorectal origin recapitulates patient heterogeneity. <i>Laboratory Investigation</i> , 2020, 100, 1465-1474.	3.7	17
72	Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study. <i>Modern Pathology</i> , 2020, 33, 2626-2636.	5.5	17

#	ARTICLE	IF	CITATIONS
73	AKT3 Expression in Mesenchymal Colorectal Cancer Cells Drives Growth and Is Associated with Epithelial-Mesenchymal Transition. <i>Cancers</i> , 2021, 13, 801.	3.7	16
74	Cancer stem cells don't waste their time cleaning—low proteasome activity, a marker for cancer stem cell function. <i>Annals of Translational Medicine</i> , 2016, 4, 519-519.	1.7	15
75	Interconnectivity between molecular subtypes and tumor stage in colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 850.	2.6	14
76	Integrated single-cell analysis unveils diverging immune features of COVID-19, influenza, and other community-acquired pneumonia. <i>ELife</i> , 2021, 10, .	6.0	12
77	Continuous clonal labeling reveals uniform progenitor potential in the adult exocrine pancreas. <i>Cell Stem Cell</i> , 2021, 28, 2009-2019.e4.	11.1	11
78	The Use of Targeted Therapies for Precision Medicine in Oncology. <i>Clinical Chemistry</i> , 2016, 62, 1556-1564.	3.2	10
79	Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. <i>British Journal of Cancer</i> , 2021, 125, 1080-1088.	6.4	10
80	Mimicking and surpassing the xenograft model with cancer-on-chip technology. <i>EBioMedicine</i> , 2021, 66, 103303.	6.1	9
81	Intestinal stem cell dynamics in homeostasis and cancer. <i>Trends in Cancer</i> , 2022, 8, 416-425.	7.4	9
82	Keeping Stem Cells in Check: A Hippo Balancing Act. <i>Cell Stem Cell</i> , 2013, 12, 3-5.	11.1	8
83	Balancing signals in the intestinal niche. <i>EMBO Journal</i> , 2017, 36, 389-391.	7.8	8
84	Intestinal region-specific Wnt signalling profiles reveal interrelation between cell identity and oncogenic pathway activity in cancer development. <i>Cancer Cell International</i> , 2020, 20, 578.	4.1	8
85	High-Fat Diet Impacts on Tumor Development in the Gut. <i>Trends in Cancer</i> , 2021, 7, 664-665.	7.4	8
86	Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. <i>Cell Reports</i> , 2021, 37, 109852.	6.4	8
87	Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. <i>Cancers</i> , 2021, 13, 3295.	3.7	7
88	Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 394.	2.6	7
89	Stem cell competition: how speeding mutants beat the rest. <i>EMBO Journal</i> , 2014, 33, 2277-2278.	7.8	6
90	The recurring features of molecular subtypes in distinct gastrointestinal malignancies—A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 164, 103428.	4.4	6

#	ARTICLE	IF	CITATIONS
91	Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. <i>Nature Genetics</i> , 2021, 53, 9-10.	21.4	6
92	Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes. <i>Molecular Oncology</i> , 2022, 16, 2693-2709.	4.6	6
93	A marker-independent lineage-tracing system to quantify clonal dynamics and stem cell functionality in cancer tissue. <i>Nature Protocols</i> , 2019, 14, 2648-2671.	12.0	4
94	Intestinal organoid co-culture protocol to study cell competition in vitro. <i>STAR Protocols</i> , 2022, 3, 101050.	1.2	4
95	Polycomb complex PRC1 as gatekeeper of intestinal stem cell identity. <i>Stem Cell Investigation</i> , 2016, 3, 22-22.	3.0	3
96	Stem Cells: All that Is Solid Melts into Air. <i>Cell Stem Cell</i> , 2017, 21, 5-7.	11.1	3
97	What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 249-261.	3.8	3
98	CD31-positive microvessel density within adenomas of Lynch Syndrome patients is similar compared to adenomas of non-Lynch patients. <i>Endoscopy International Open</i> , 2019, 07, E701-E707.	1.8	3
99	Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content – a short report. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 397-403.	4.4	3
100	Rebuttal to: Digesting the Importance of Cell Fusion in the Intestine. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 303.	4.5	2
101	Pre-Operative Decitabine in Colon Cancer Patients: Analyses on WNT Target Methylation and Expression. <i>Cancers</i> , 2021, 13, 2357.	3.7	2
102	Turning off the BCL-2 switch to prevent intestinal tumorigenesis. <i>Oncotarget</i> , 2016, 7, 28763-28764.	1.8	2
103	The Effect of Dynamic, In Vivo-like Oxaliplatin on HCT116 Spheroids in a Cancer-on-Chip Model Is Representative of the Response in Xenografts. <i>Micromachines</i> , 2022, 13, 739.	2.9	2
104	A Cancer Stem Cell Perspective on Minimal Residual Disease in Solid Malignancies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 31-49.	0.1	1
105	Cancer stem cells: here, there, and everywhere. <i>Molecular and Cellular Oncology</i> , 2019, 6, 1540235.	0.7	1
106	474P Prognostic and predictive role of Consensus Molecular Subtypes (CMS) determined by immunohistochemistry in metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2020, 31, S442-S443.	1.2	1
107	Predicting survival of cancer patients by chromosomal copy number heterogeneity. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1949956.	0.7	1
108	Cancer Stem Cells in Colorectal Cancer. , 2009, , 223-250.		1

#	ARTICLE	IF	CITATIONS
109	Copy number heterogeneity as high risk feature of stage II colon cancer. Journal of Pathology, 2022, , .	4.5	1
110	Quantitative models for the inference of intratumor heterogeneity. Computational and Systems Oncology, 2022, 2, .	1.5	1
111	Confusion on Cell Fusion. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 304-306.	4.5	0
112	Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer. , 2021, , 259-288.		0
113	Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1726-1734.	2.5	0
114	Abstract 603: Consensus molecular subtyping through a community of experts advances unsupervised gene expression-based disease classification and facilitates clinical translation. , 2015, , .		0
115	Abstract LB-108: Automated immunohistochemistry-based identification of molecular subtypes in colorectal cancer. , 2015, , .		0
116	Abstract 5177: Heterogeneity of pancreatic ductal adenocarcinoma visualized. , 2015, , .		0
117	Abstract 5273: Role of methylation of Wnt target genes in tumorigenesis and effect of re-expression with demethylating agent decitabine in colon cancer. , 2015, , .		0
118	Phenotypic subtypes as a novel validated prognostic classification system for patients with colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 625-625.	1.6	0